Nature:线粒体蛋白调节脂代谢抑制乳腺癌细胞增殖

2017-03-23 Leo.C MedSci原创

线粒体蛋白调节脂代谢抑制乳腺癌细胞增殖

不同于恶性生长的新生肿瘤细胞,正常细胞在减数分裂之后开始展现出抑制细胞生长的特性,其中包括表达一系列抑制细胞周期的蛋白。因此比较这些已经分化后的细胞也许能找到新的一些抑制细胞生长的基因,从而有可能成为抑制肿瘤细胞生长的关键因素。

在最新上线的Nature杂志中,Zuzana Keckesova及其同事,发现线粒体蛋白LACTB能够通过调节细胞的脂代谢从而抑制乳腺癌细胞的增殖。

乳腺,肺和大肠这些器官组织产生癌细胞的几率要大于心脏,肌肉和大脑。这种现象暗示了分化成心脏,肌肉和大脑中的细胞可能有特定的基因特征,使他们不容易癌变从而恶性生长。本文的研究组通过比较实验小鼠和人的肌肉细胞与各种癌细胞发现一种LACTB的基因在癌细胞中的表达量特定下调,但是在其他正常细胞,如肌肉,心脏和肝中普遍表达。

通过体外实验和癌细胞移植实验发现,在癌细胞内诱导表达LACTB蛋白能够抑制乳腺癌细胞的增殖与分化。因为LACTB是一种线粒体的内网蛋白,研究组试图阐述是否LACTB通过调节线粒体的功能从而抑制癌细胞的增殖。研究者发现,在乳腺癌细胞增殖分化的前24小时内,表达LACTB并没有造成任何的包括ATP和氧化自由基(ROS)的产量的不同,线粒体膜功能的不同或者线粒体数量及结构的不同。然而,当癌细胞分化到后期(3-6天),LACTB的表达导致上述的线粒体的功能产生明显不同。通过质谱分析诱导表达LACTB后的癌细胞发现,溶血磷脂酰乙醇胺(lysophosphatidylethanolamines, LPE)以及磷酯酰乙醇胺(phosphatidylethanolamines,PE)的产生在诱导LACTB的表达的24小时内大幅下降。研究人员在培养癌细胞的培养基中加入了溶血磷脂酰乙醇胺发现其能促进癌细胞的增殖和分化。从而表明诱导表达LACTB蛋白是通过抑制癌细胞的溶血磷脂酰乙醇胺从而抑制癌细胞的增殖与分化。

这项研究发现了一个具有抑制癌细胞增长功能的新的线粒体蛋白,也将线粒体的脂代谢功能和乳腺癌细胞的生长和增殖联系起来。

原始出处:
Zuzana Keckesova, Joana Liu Donaher, Jasmine De Cock et al., LACTB is a tumour suppressor that modulates lipid metabolism and cell state. Nature (2017) doi:10.1038/nature21408

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1701025, encodeId=53b01e01025de, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Wed Feb 21 05:15:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881789, encodeId=4d791881e8968, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 01 13:15:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252208, encodeId=f4d712522085d, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Mar 25 04:15:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540884, encodeId=3d7e15408842b, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Sat Mar 25 04:15:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597067, encodeId=902b159e067eb, content=<a href='/topic/show?id=e7f6842982d' target=_blank style='color:#2F92EE;'>#脂代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84298, encryptionId=e7f6842982d, topicName=脂代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3218475330, createdName=huangdf, createdTime=Sat Mar 25 04:15:00 CST 2017, time=2017-03-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1701025, encodeId=53b01e01025de, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Wed Feb 21 05:15:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881789, encodeId=4d791881e8968, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 01 13:15:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252208, encodeId=f4d712522085d, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Mar 25 04:15:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540884, encodeId=3d7e15408842b, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Sat Mar 25 04:15:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597067, encodeId=902b159e067eb, content=<a href='/topic/show?id=e7f6842982d' target=_blank style='color:#2F92EE;'>#脂代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84298, encryptionId=e7f6842982d, topicName=脂代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3218475330, createdName=huangdf, createdTime=Sat Mar 25 04:15:00 CST 2017, time=2017-03-25, status=1, ipAttribution=)]
    2017-12-01 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1701025, encodeId=53b01e01025de, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Wed Feb 21 05:15:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881789, encodeId=4d791881e8968, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 01 13:15:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252208, encodeId=f4d712522085d, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Mar 25 04:15:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540884, encodeId=3d7e15408842b, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Sat Mar 25 04:15:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597067, encodeId=902b159e067eb, content=<a href='/topic/show?id=e7f6842982d' target=_blank style='color:#2F92EE;'>#脂代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84298, encryptionId=e7f6842982d, topicName=脂代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3218475330, createdName=huangdf, createdTime=Sat Mar 25 04:15:00 CST 2017, time=2017-03-25, status=1, ipAttribution=)]
    2017-03-25 yxch36
  4. [GetPortalCommentsPageByObjectIdResponse(id=1701025, encodeId=53b01e01025de, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Wed Feb 21 05:15:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881789, encodeId=4d791881e8968, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 01 13:15:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252208, encodeId=f4d712522085d, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Mar 25 04:15:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540884, encodeId=3d7e15408842b, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Sat Mar 25 04:15:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597067, encodeId=902b159e067eb, content=<a href='/topic/show?id=e7f6842982d' target=_blank style='color:#2F92EE;'>#脂代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84298, encryptionId=e7f6842982d, topicName=脂代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3218475330, createdName=huangdf, createdTime=Sat Mar 25 04:15:00 CST 2017, time=2017-03-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1701025, encodeId=53b01e01025de, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Wed Feb 21 05:15:00 CST 2018, time=2018-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881789, encodeId=4d791881e8968, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 01 13:15:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252208, encodeId=f4d712522085d, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Mar 25 04:15:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540884, encodeId=3d7e15408842b, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Sat Mar 25 04:15:00 CST 2017, time=2017-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597067, encodeId=902b159e067eb, content=<a href='/topic/show?id=e7f6842982d' target=_blank style='color:#2F92EE;'>#脂代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84298, encryptionId=e7f6842982d, topicName=脂代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce3218475330, createdName=huangdf, createdTime=Sat Mar 25 04:15:00 CST 2017, time=2017-03-25, status=1, ipAttribution=)]
    2017-03-25 huangdf

相关资讯

JAMA:化疗后一定要掉头发吗?新技术或可改变这一现状

掉发是癌症治疗过程中最严重的副作用之一。而科学家们早在80年代就指出通过冷却患者的头皮,能够有效避免化疗过程中头发掉落的问题。2015年,一种叫做DigniCap的冷却设备被FDA批准用于女性乳腺癌治疗的过程中。

J Natl Cancer Inst:值夜班对乳腺癌发病率影响较小或无影响

近些年女性患乳腺癌的几率越来越高,也许跟现代女性工作压力、生活压力导致的生活习惯的改变等都有一定关系。2016年10月,发表在《J Natl Cancer Inst.》的一篇3项前瞻性研究和已发表研究的荟萃分析调查了值夜班对乳腺癌发病率的影响。

Lancet:HERA 研究 11 年随访:曲妥珠单抗可提高 Her2 阳性乳腺癌生存

曲妥珠单抗可显着提高 HER-2 阳性乳腺癌患者的总生存期(OS)和无病生存期(DFS),但目前尚无相关长期随访数据。

新药有望替代生物治疗治愈乳腺癌

专家说:“许多女性可以通过一种新型的乳腺癌药物来帮助生物治疗,目前只能作为临床试验的一部分。但是,在不久的将来有很大的希望被用于单独治疗乳腺癌”。专家估计,多达五分之一的患者可能受益。科学家说:“英国每年约有 10,000 名妇女可能受益于新型乳腺癌治疗”。生物治疗可以帮助抵抗罕见的遗传错误导致的乳腺癌,如 BRCA 一个女演员安吉丽娜·朱莉携带了一种罕见的遗传错误基因,从而患有一种区别于

Mol Cell:耐药性的关键被突破,乳腺癌有望通过药物得到治疗

四分之三的乳腺癌肿瘤由雌性激素驱动。这些肿瘤经常用药物治疗以抑制雌激素受体活性,但不幸的是,至少一半的患者对这些治疗没有反应,使它们成为耐药性肿瘤。 现在,来自斯克里普斯研究所(TSRI),加利福尼亚大学(UC),圣地亚哥和伊利诺伊大学的佛罗里达州校园的科学家发现两种免疫系统分子可能是雌激素,驱动乳腺癌。研究人员认为,这一发现可能为成千上万患有雌激素驱动的乳腺癌的患者开创了

Sci Rep:高血压是否增加乳腺癌的发病风险?

目前,关于高血压与乳腺癌风险之间相关性的研究存在一定的矛盾。近期,一项发表在杂志Sci Rep上的研究进行了系统评价和荟萃分析,总结了有关高血压与乳腺癌风险之间的相关证据。通过对PubMed、EMBASE和Cochrane图书馆的综合文献检索,确定截至2016年8月的相关合格研究。此项荟萃分析包括报告了相对风险(RR)与相应95%置信区间(CI)的观察性研究。通过使用随机效应模型汇集个人研究结果。